Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy

Ye, Tai-Wei; Wang, Dongdong; Lu, Wei; Xie, Ya-Ming; Xu, Fei-Qi; Fu, Tian-Wei; Zhang, Kang-Jun; Liu, Siyu; Xie, Guofeng; Cheng, Jian; Jiang, Kai; Xiao, Zunqiang; Yao, Weifeng; Shen, Ge; Liu, Jun-Wei; Huang, Dongsheng; Zhang, Chengwu; Liang, Lei

doi:10.1080/17474124.2023.2192479

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SBRT is also a rising local treatment modality, demonstrating robust local control rates of 91% for tumors smaller than 5 cm and 74% for tumors measuring 5 cm or larger [32]. Conventional TACE exhibited a recurrence rate in cases of early-stage HCC with a complete response to treatment (CR) that was not higher than observed in surgery as well [20,33].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Transarterial Chemoembolization (TACE) for Early-Stage Hepatocellular Carcinoma

Lee,

Shin

2023

Medicina

View full text Add to dashboard Cite

Backgound and Objectives: The treatments of choice for patients with early-stage hepatocellular carcinoma (HCC) are surgical resection, local ablation therapy, and liver transplantation; however, transarterial chemoembolization (TACE) is commonly performed due to variations among patients and liver diseases. This study aimed to assess the efficacy of TACE in patients with early-stage HCC. Materials and Methods: A retrospective analysis was performed of all TACE procedures performed at Kyung Hee University Hospital at Gangdong over a 15-year period (July 2006 to November 2021). The study included a total of 97 eligible patients with early-stage HCC ≤ 5 cm initially treated with TACE. The mean participant age was 63.47 ± 11.02 years; 69 were men (71.1%). The number of Child–Pugh class A patients was the highest (74 patients [76.3%]), followed by Child–Pugh class B (19 patients [19.6%]) and Child–Pugh class C (4 patients [4.12%]). Results: A complete response was achieved in 84 (86.6%) patients after the first TACE procedure, with 1-, 2-, and 3-year survival rates of 91.8%, 87.3%, and 75.4%, respectively. In the multivariate analysis, the patients with a low initial alpha-fetoprotein (AFP) ≤ 20 ng/mL (p = 0.02) and a complete response after the first TACE (p = 0.03) were associated with favorable overall survival. Conclusions: TACE can be used to treat patients with early-stage HCC who are unsuitable for ablation or surgery. If patients are well selected, TACE may be an alternative treatment for patients with low AFP levels who respond well to the initial TACE procedure.

show abstract

Section: Discussionmentioning

confidence: 99%